Acesian Partners First Half 2025 Earnings: S$0.004 loss per share (vs S$0.002 profit in 1H 2024)
Key Financial Results
Revenue: S$2.12m (down 58% from 1H 2024).
Net loss: S$1.95m (down by 273% from S$1.13m profit in 1H 2024).
S$0.004 loss per share (down from S$0.002 profit in 1H 2024).
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Acesian Partners shares are down 5.6% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Acesian Partners that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
MVV Energie Third Quarter 2025 Earnings: EPS: €0.36 (vs €0.38 in 3Q 2024)
Explore MVV Energie's Fair Values from the Community and select yours MVV Energie (ETR:MVV1) Third Quarter 2025 Results Key Financial Results Revenue: €1.35b (up 3.4% from 3Q 2024). Net income: €23.7m (down 4.4% from 3Q 2024). Profit margin: 1.7% (down from 1.9% in 3Q 2024). The decrease in margin was driven by higher expenses. EPS: €0.36 (down from €0.38 in 3Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period MVV Energie's share price is broadly unchanged from a week ago. Risk Analysis Before we wrap up, we've discovered 2 warning signs for MVV Energie (1 is significant!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
PolyPeptide Group First Half 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore PolyPeptide Group's Fair Values from the Community and select yours PolyPeptide Group (VTX:PPGN) First Half 2025 Results Key Financial Results Revenue: €167.1m (up 24% from 1H 2024). Net loss: €26.5m (loss widened by 133% from 1H 2024). €0.80 loss per share (further deteriorated from €0.35 loss in 1H 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period PolyPeptide Group Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 40%. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Performance of the Swiss Life Sciences industry. The company's shares are up 25% from a week ago. Risk Analysis Before we wrap up, we've discovered 1 warning sign for PolyPeptide Group that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
9 minutes ago
- Yahoo
Fastned B.V First Half 2025 Earnings: €0.94 loss per share (vs €0.59 loss in 1H 2024)
Explore Fastned B.V's Fair Values from the Community and select yours Fastned B.V (AMS:FAST) First Half 2025 Results Key Financial Results Revenue: €58.6m (up 55% from 1H 2024). Net loss: €18.3m (loss widened by 60% from 1H 2024). €0.94 loss per share (further deteriorated from €0.59 loss in 1H 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Fastned B.V Earnings Insights Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Specialty Retail industry in Europe. Performance of the market in the Netherlands. The company's shares are up 3.2% from a week ago. Risk Analysis Before you take the next step you should know about the 1 warning sign for Fastned B.V that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
